Dear shareholders,
It is a privilege to share this message as Suven Life Sciences marks
another year of meaningful progress. Our clinical-stage programs have advanced steadily,
and we've made commendable strides in advancing our early-stage research pipeline.
The encouraging results from our Phase 2 study of Samelisant have
provided strong momentum to advance our development strategy. We are now initiating a
Phase 3 study targeting excessive daytime sleepiness (EDS). Moreover, we recognise a
broader landscape of opportunities for Samelisant beyond narcolepsy, such as cataplexy in
narcolepsy, idiopathic hypersomnia and other indications which we can explore to expand
the molecule's therapeutic reach.
We made meaningful progress in the Phase 3 clinical trials of our
leading candidate, Masupirdine. This multi-country study, targeting a patient cohort of
over 375 patients, has so far achieved 36%. We anticipate topline data to be available in
Q1/Q2-2027.
We also engaged with the FDA to seek guidance on the design of the
Phase 2 study for Usmarapride. I'm pleased to share that with this molecule advancing
to the next stage, over 25% of our pipeline will be in Phase 2 clinical development,
marking a significant milestone in our R&D progression.
Our latest clinical-stage entrant, SUVN-I6107, has received FDA
clearance following acceptance of the IND, along with a "Study May Proceed"
letter for the Phase 1 trial. We have since initiated the study in the United States.
These milestones reflect the tangible impact of our sustained focus on
embedding our improved operational strategies, enabling a greater number of our molecular
assets to advance meaningfully along their development and clinical pathways.
With cash reserves declining to C 61.40 crore as of March 31, 2025, the
Board approved the preferential issuance of 6.4 crore convertible warrants, successfully
raising C 857 crore priced at C 134 per warrant. This capital infusion is intended to
support a range of strategic initiatives spanning R&D, ongoing clinical trials, and
establishing a new research facility.
We are making a substantial investment in a state-of-the-art R&D
centre at Chandapur village, Sangareddy District.
This facility will be equipped with advanced instrumentation and
next-generation technologies. Once operational, it will significantly enhance our
scientific capabilities, enabling us to execute complex chemical processes with greater
precision, efficiency, and scale. We may also leverage this facility to assist other
innovation programs.
The next 24–36 months will be pivotal for Suven Life Sciences, as
we anticipate topline data from several of our lead clinical programs. These outcomes hold
the potential to shape the trajectory of our pipeline and reafirm the strength of our
scientific foundation.
At the heart of this journey lies an unshakable belief in possibility.
Our collective resolve is anchored in the vision of advancing even one transformative
molecule to its full potential. That singular achievement would not only reflect our
team's unwavering dedication but also etch our contribution into the fabric of
scientific progress–leaving a legacy that transcends generations.
As we look ahead, I want to extend my heartfelt gratitude to our valued
shareholders, partners, directors, employees and stakeholders. Your belief in our vision,
trust in our capabilities, and unwavering support have been the cornerstone of our
continued progress. This journey has demanded resilience, and your encouragement has been
instrumental in shaping every step forward.
Warm regards,
Venkateswarlu Jasti
Chairman & MD